vimarsana.com

Latest Breaking News On - Hedge funds weigh in on merrimack pharmaceuticals - Page 1 : vimarsana.com

Merrimack Pharmaceuticals (NASDAQ:MACK) Cut to Sell at StockNews com

StockNews.com cut shares of Merrimack Pharmaceuticals (NASDAQ:MACK – Free Report) from a hold rating to a sell rating in a research report released on Monday morning. Merrimack Pharmaceuticals Trading Up 0.1 % Merrimack Pharmaceuticals stock opened at $15.13 on Monday. The firm has a market capitalization of $219.84 million, a P/E ratio of -189.13 and […]

Merrimack Pharmaceuticals (NASDAQ:MACK) Shares Cross Above 200-Day Moving Average of $12 40

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK – Get Free Report) shares passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $12.40 and traded as high as $13.39. Merrimack Pharmaceuticals shares last traded at $13.32, with a volume of 36,749 shares. Analyst Ratings Changes Separately, StockNews.com upgraded shares […]

Merrimack Pharmaceuticals, Inc (NASDAQ:MACK) Director Acquires $1,298,492 50 in Stock

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK – Get Free Report) Director Eric Andersen bought 101,050 shares of the company’s stock in a transaction that occurred on Thursday, December 7th. The stock was bought at an average cost of $12.85 per share, for a total transaction of $1,298,492.50. Following the completion of the transaction, the director now directly […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.